ORLANDO, FL - March 02, 2026 - PRESSADVANTAGE - WhiteSands Treatment Center has published a new educational resource on ...

"AtaiBeckley’s MDMA-based drug for anxiety shows benefit in Phase IIa trial" was originally created and published by Clinical ...

The proportion of American adults who took anxiety medications jumped from 11.7% in 2019 to 14.3% in 2024, with most of the ...

People who experience high levels of social anxiety tend to view neutral or ambiguous interactions as intentionally hostile, but treating the anxiety can effectively reduce this aggressive perception, ...

Anxiety isn’t just about feeling stressed or worried. For millions of Americans it’s a daily battle that affects everything from relationships to career choices. With 31% of adults experiencing an ...

In a groundbreaking stride toward transforming the landscape of anxiety treatment, biopharmaceutical company VistaGen has unveiled promising top-line results from its Phase 3 PALISADE-2 trial. This ...

When people struggle with anxiety and depression, the most effective approach is often to combine medication and ...

In this post I review the benefits and limitations of conventional treatments of anxiety disorders. Future posts in this series will discuss complementary and alternative approaches used to treat ...

AtaiBeckley NV (NASDAQ:ATAI, XETRA:9VC) reported positive topline results from an exploratory Phase 2a trial evaluating its ...

Cognitive behavioral therapy (CBT) should be considered first-line treatment for generalized anxiety disorder in adults, according to a systematic review and network meta-analysis of 66 randomized ...

Please provide your email address to receive an email when new articles are posted on . Treatment of generalized anxiety disorder with an antidepressant increased the treatment response rate by 41%.

Low choline levels in the brain are associated with anxiety disorders, research has found. Experts explain what choline is ...